GUERBET : 3rd quarter 2016 revenue
October 24 2016 - 11:55AM
Revenue at September 30, 2016
Sales variance stabilized at -2.3% at constant
exchange rates
Level of sales in line with expectations
Guerbet (FR0000032526 GBT), a global specialist in contrast
agents and solutions for medical imaging, is reporting revenue of
€568.4 million at September 30, 2016, up 65.4% from 2015,
continuing the momentum started in the first half of 2016. This
growth figure includes a negative currency impact of €13.4 million
mainly from the Brazilian real and the Argentine peso. At constant
exchange rates, the Group posted sales of €581.9 million, a limited
decrease of 2.3% from the pro forma sales at the end of September
2015 and still in line with the sales stabilization target of
+/-3%. With revenue of €191.7 million for third quarter 2016, the
strong sales momentum remains comparable with second quarter 2016
(€193.0 million).
Consolidated Group revenue (IFRS)
In
millions of euros |
9 months
2016 |
9
months 2015 pro forma* |
Change |
Reported 2015 |
1st half
2016 |
1st half
2015 pro forma |
Change |
Sales in Europe |
274.3 |
282.7 |
-2.9% |
236.7 |
189.7 |
187.5 |
+1.2% |
Sales in Other Markets |
294.1 |
313.1 |
-6.1% |
106.9 |
187.0 |
210.3 |
-11.1% |
Total |
568.4 |
595.8 |
-4.6% |
343.6 |
376.7 |
397.8 |
-5.3% |
* Integration of CMDS activities
At constant exchange rates, sales growth is
in line with the revenue stabilization objective (+/-3%)
In Europe, consolidated revenue at September 30,
2016 totaled €274.3 million compared with €282.7 million in 2015 in
its pro forma version, including a negative currency impact of €2.8
million. The decline in sales was mainly confined to Russia. The
region's third-quarter revenue totaled €84.6 million compared with
€95.1 million in 2015 (pro forma).
Outside Europe, the Group's sales fell to €294.1
million compared with €313.1 million in 2015 (pro forma), including
a negative currency effect of €10.6 million. At constant exchange
rates, there was a slight decrease of 2.7%, benefiting particularly
from sales of Dotarem® in the US. Third-quarter revenue in Other
Markets increased to €107.1 million compared with €102.8 million in
2015 (pro forma).
Favorable momentum in MRI and IRT, growth
expected in X-ray and ISS
At constant exchange rates, the activity breaks
down as follows:
- revenue for MRI totaled €183.2 million, up 3.7% (€176.6
million pro forma 2015),
- the X-Ray segment was down 5.9% at €282.5 million, still
mainly due to Optiray®,
- the IRT segment grew 22.3%, exceeding €40 million in
revenue, thanks to the performance of Lipiodol® and Patent
Blue V,
- lastly, the Imaging Solutions and Services (ISS)
segment was down 5.9% with revenue of €58.1 million.
2016 outlook: confirmation of annual
targets
The performance level for the first nine months
of the year is within the window of +/-3% announced as the
full-year target, allowing the Group to confirm this goal.
Upcoming events:
2016 revenue: February 15, 2017, after
trading
About Guerbet
Guerbet is a pioneer in the contrast agent
field, with 90 years' experience, and is the only pharmaceutical
group dedicated to medical imaging worldwide. It offers a
comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and
Interventional Radiology and Theranostics (IRT) products, along
with a range of injectors and related medical devices to improve
the diagnosis and treatment of patients. To discover new products
and ensure future growth, Guerbet invests heavily in R&D,
spending around 9% of its sales each year. Guerbet (GBT) is listed
on Euronext Paris (Segment B - Mid Caps) and generated €789 million
in pro forma revenue in 2015.
For more information about Guerbet, please visit
www.guerbet.com
Contacts
Jean-François Le
Martret Chief Financial Officer (+33)(0)1 45 91 50 00
|
Financial Communications
Benjamin Lehari (+33)(0)1 56 88 11 25 blehari@actifin.fr
Press Jennifer Jullia (+33)(0)1 56 88 11 19
jjullia@actifin.fr |
GUERBET : 3rd quarter 2016 revenue
http://hugin.info/159769/R/2050953/767264.pdf
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024